Yasho Industries Ltd

- Yasho Industries is currently focusing on reducing its debt-to-EBITDA ratio to a comfort zone of around 2.5x. - The company does not plan to increase debt significantly until this ratio is achieved, although the absolute debt number might rise. - The INR125 crores capex planned for FY27 will be funded through internal accruals, not through new strategic debt or equity. - There is no mention of any immediate equity fundraising. - The company aims to manage working capital efficiently and maintain financial discipline without aggressive new fundraising in the short term.

- FY '26 capex: INR 75 crores, including INR 42 crores at Pakhajan and about INR 7-8 crores at Vapi; INR 25 crores spent on R&D. - FY '27 planned capex: INR 125 crores, purely at Pakhajan; no capex contribution from the MNC project (separate). - Additional special project at Pakhajan with INR 90 crores capex ongoing. - Future capacity expansion at Pakhajan involves building additional production buildings (4 more possible). - Long-term contract signed in FY '26 with an advance of INR 51.4 crores; revenue expected from this starting FY '28. - No CDMO-style capex; focus on large-volume production (minimum 500-1,000 metric tons). - The company aims to reach 75%+ utilization by FY '28, supported by capacity expansions and leveraging strategic contracts.

- FY26 volume growth was 33% year-on-year. - FY27 volume growth expected to be between 40% to 50%, driven by 15% increase in capacity utilization. - Capacity utilization targeted to ramp up to 75% by FY27. - FY28 revenue guidance is approximately INR 1,500 crores, including: - Capacity expansion done in FY26. - Commercialization of a long-term contract/project contributing to growth. - Volume growth primarily driven by the industrial segment; consumer segment may see slight dip. - Prices stable overall, with some volatility in specific solvents; price increases of 10-15% expected starting FY27. - Beyond FY28, growth will be fueled by leveraging current assets at higher utilization (85-90%), introducing new molecules/products, and expanding into performance chemicals beyond traditional segments.

- Volume growth expected between 35% to 45% in FY27, with capacity utilization increasing by about 15%. - Targeting revenue of approximately INR1,500 crores by FY28, driven by capacity expansions and a long-term contract operational from FY28. - EBITDA margins anticipated to improve by 2-3%, supported by higher utilization (70%-75% in FY27) and operational efficiencies, targeting around 20%+ EBITDA margin. - Gross margins expected to be stable between 40%-42% in the medium term, due to improved asset utilization and cost rationalization. - FY27 capex planned at INR125 crores, funded entirely via internal accruals, expected to support new product launches and capacity expansions. - Long-term 15-year contract provides revenue visibility from FY28 onwards, backed by INR51.4 crores advance received. - Despite global challenges, operational and financial discipline aims to deliver consistent and profitable growth.

- The management did not explicitly mention a current or expected order book value during the call. - However, there is reference to commitments from customers based on gained confidence due to supply reliability, supporting the guidance of 70%-75% capacity utilization. - A strategic large project for an MNC is expected to start contributing commercially from early FY28, indicating some secured future orders. - About 40% of revenue in Q4 FY26 came from contracts with fixed pricing (quarterly or 6-monthly), and 60% from spot or regular customers, implying a mix of confirmed and variable orders. - There is no disclosed exact monetary value or backlog figure disclosed for pending orders. - Management emphasized healthy demand visibility and customer penetration, but did not quantify order book size.